Previous 10 | Next 10 |
LEXINGTON, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Chief Executive Officer (CEO), John Sperzel, has promoted Tony Pare to t...
On a preliminary basis , T2 Biosystems (NASDAQ: TTOO ) expects Q4 revenue of ~$3.0M, including ~$1.5M in product sales. It also closed 10 T2Dx contracts in the quarter. More news on: T2 Biosystems, Inc., Healthcare stocks news, Stocks on the move, Read more ...
LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced preliminary revenue and business results for the three months ended December 31, ...
LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Board of Directors has appointed diagnostics industry veteran John Sperz...
Aravive (NASDAQ: ARAV ) +212% on promise of lead candidate . More news on: Aravive, Inc., Cancer Genetics, Inc., My Size, Inc., Stocks on the move, Read more ...
LEXINGTON, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company,”“T2,” or “T2 Biosystems”), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in h...
T2 Biosystems, Inc. (TTOO) Q3 2019 Earnings Conference Call November 12, 2019 8:30 a.m. ET Company Participants Zack Kubow - W2O Group John McDonough - Chairman and CEO John Sprague - CFO Tom Lowery - Chief Scientific Officer Conference Call Participants Puneet Souda - SV...
Solid Biosciences (NASDAQ: SLDB ) -71% on another clinical hold on DMD gene therapy . More news on: Solid Biosciences Inc., Diplomat Pharmacy, Inc., Fluent, Inc., Stocks on the move, Read more ...
T2 Biosystems ( TTOO ) Q3 results : Revenues: $1.6M; Product revenue: $1.4M (+17%); Research and grant contribution revenues: $0.2M. More news on: T2 Biosystems, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
LEXINGTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company,”“T2,” or “T2 Biosystems”), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in h...
News, Short Squeeze, Breakout and More Instantly...
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after mar...
Shares of Nucor Corporation (NYSE:NUE) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financia...